La Jolla Pharma (LJPC) 16.92 $LJPC
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference
BusinessWire - Mon Jun 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will provide a corporate overview at the Jefferies 2016 Global Healthcare Conference taking place June 7-10 in New York City.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical posts 1Q loss
Automated Insights - Fri May 06, 8:07AM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Friday reported a loss of $16.5 million in its first quarter.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Fri May 06, 8:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress.
LJPC: 16.92 (-0.08)
New 52-Week Low Could Prompt More Insider Buying At LJPC
TheOnlineInvestor.com - Fri Jan 15, 12:28PM CST
In trading on Friday, shares of La Jolla Pharmaceutical Co. touched a new 52-week low of $14.01/share.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
BusinessWire - Mon Nov 30, 7:00AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/575,127, entitled "Angiotensin II Alone or in Combination for the Treatment of Hypotension," which covers LJPC-501, La Jolla's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). LJPC-501 is currently the subject of a Phase 3 clinical trial for the treatment of CRH, and results from this trial are expected by the end of 2016.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
BusinessWire - Mon Oct 19, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of LJPC-401, La Jolla's novel formulation of hepcidin.
LJPC: 16.92 (-0.08)
Orphan Drug Designation For Novel Compounds - Report on La Jolla Pharmaceutical
PR Newswire - Wed Sep 16, 8:20AM CDT
ACI Association has initiated research coverage on La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company concludes public offering of 2.93m common stock
M2 - Wed Sep 16, 4:35AM CDT
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) reported on Tuesday that it has completed its underwritten public offering of 2,932,500 shares of common stock.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Closes Offering of Common Stock
BusinessWire - Tue Sep 15, 3:10PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the closing of its underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share, which includes the exercise of the underwriters' option to purchase up to an additional 382,500 shares of common stock. Gross offering proceeds are approximately $111.4 million, including proceeds from the exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
BusinessWire - Fri Sep 11, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla", a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-401, La Jolla's novel formulation of hepcidin, for designation as an orphan medicinal product for the treatment of chronic iron overload requiring chelation therapy. Chronic iron overload occurs in patients suffering from beta thalassemia, sickle cell disease and hereditary hemochromatosis (HH). The final opinion, which is subject to review and approval by the European Commission (EC), may include all or a subset of these conditions.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
BusinessWire - Thu Sep 10, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla", a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten offering of 2,550,000 shares of its common stock, offered at a price of $38.00 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 382,500 shares of common stock. The offering is expected to close on or about September 15, 2015, subject to customary closing conditions. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners are acting as co-managers for the offering.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company to launch underwritten offering of common shares
M2 - Thu Sep 10, 3:26AM CDT
Biopharmaceutical therapies company La Jolla Pharmaceutical Company (Nasdaq:LJPC) stated on Wednesday that it plans to offer its common stock in an underwritten offering.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Rises 26.5%
Zacks Equity Research - Zacks Investment Research - Wed Sep 09, 8:48AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as its shares rose almost 27% on the day.
LJPC: 16.92 (-0.08), IG: 7.68 (+1.41)
La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 7:59AM CDT
La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
LJPC: 16.92 (-0.08)
3 Biotech Stocks Bucking the Stock Market Crash
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 28, 1:02PM CDT
Source: National Cancer Institute. The past week on Wall Street has been downright ugly. For five straight sessions panic has pushed all three major market indexes lower by double-digit percentages. Although stock market corrections are a...
LXRX: 16.42 (+0.10), LJPC: 16.92 (-0.08), ACOR: 25.23 (-0.05)
La Jolla Pharmaceutical Company awarded US FDA's orphan drug designation for two novel compounds for FOP
M2 - Wed Aug 19, 5:53AM CDT
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) revealed on Tuesday that it has received the US Food and Drug Administration (FDA) Office of Orphan Products Development's orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva (FOP).
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva
BusinessWire - Tue Aug 18, 7:05AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted La Jolla orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva (FOP).
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors
BusinessWire - Tue Aug 18, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and Vanderbilt University (Vanderbilt) today announced an exclusive, worldwide research and license agreement covering Vanderbilt's research program and intellectual property rights relating to small-molecule kinase inhibitors designed to selectively block specific members of the bone morphogenetic protein (BMP) type-I receptor family.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference
BusinessWire - Mon Jun 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will provide a corporate overview at the Jefferies 2016 Global Healthcare Conference taking place June 7-10 in New York City.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical posts 1Q loss
Automated Insights - Fri May 06, 8:07AM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Friday reported a loss of $16.5 million in its first quarter.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Fri May 06, 8:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress.
LJPC: 16.92 (-0.08)
New 52-Week Low Could Prompt More Insider Buying At LJPC
TheOnlineInvestor.com - Fri Jan 15, 12:28PM CST
In trading on Friday, shares of La Jolla Pharmaceutical Co. touched a new 52-week low of $14.01/share.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
BusinessWire - Mon Nov 30, 7:00AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/575,127, entitled "Angiotensin II Alone or in Combination for the Treatment of Hypotension," which covers LJPC-501, La Jolla's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). LJPC-501 is currently the subject of a Phase 3 clinical trial for the treatment of CRH, and results from this trial are expected by the end of 2016.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
BusinessWire - Mon Oct 19, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of LJPC-401, La Jolla's novel formulation of hepcidin.
LJPC: 16.92 (-0.08)
Orphan Drug Designation For Novel Compounds - Report on La Jolla Pharmaceutical
PR Newswire - Wed Sep 16, 8:20AM CDT
ACI Association has initiated research coverage on La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company concludes public offering of 2.93m common stock
M2 - Wed Sep 16, 4:35AM CDT
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) reported on Tuesday that it has completed its underwritten public offering of 2,932,500 shares of common stock.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Closes Offering of Common Stock
BusinessWire - Tue Sep 15, 3:10PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the closing of its underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share, which includes the exercise of the underwriters' option to purchase up to an additional 382,500 shares of common stock. Gross offering proceeds are approximately $111.4 million, including proceeds from the exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses. LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
BusinessWire - Fri Sep 11, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-401, La Jolla's novel formulation of hepcidin, for designation as an orphan medicinal product for the treatment of chronic iron overload requiring chelation therapy. Chronic iron overload occurs in patients suffering from beta thalassemia, sickle cell disease and hereditary hemochromatosis (HH). The final opinion, which is subject to review and approval by the European Commission (EC), may include all or a subset of these conditions. LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
BusinessWire - Thu Sep 10, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten offering of 2,550,000 shares of its common stock, offered at a price of $38.00 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 382,500 shares of common stock. The offering is expected to close on or about September 15, 2015, subject to customary closing conditions. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners are acting as co-managers for the offering. LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company to launch underwritten offering of common shares
M2 - Thu Sep 10, 3:26AM CDT
Biopharmaceutical therapies company La Jolla Pharmaceutical Company (Nasdaq:LJPC) stated on Wednesday that it plans to offer its common stock in an underwritten offering.
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Rises 26.5%
Zacks Equity Research - Zacks Investment Research - Wed Sep 09, 8:48AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as its shares rose almost 27% on the day.
LJPC: 16.92 (-0.08), IG: 7.68 (+1.41)
La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 7:59AM CDT
La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
LJPC: 16.92 (-0.08)
3 Biotech Stocks Bucking the Stock Market Crash
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 28, 1:02PM CDT
Source: National Cancer Institute. The past week on Wall Street has been downright ugly. For five straight sessions panic has pushed all three major market indexes lower by double-digit percentages. Although stock market corrections are a...
LXRX: 16.42 (+0.10), LJPC: 16.92 (-0.08), ACOR: 25.23 (-0.05)
La Jolla Pharmaceutical Company awarded US FDA's orphan drug designation for two novel compounds for FOP
M2 - Wed Aug 19, 5:53AM CDT
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) revealed on Tuesday that it has received the US Food and Drug Administration (FDA) Office of Orphan Products Development's orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva (FOP).
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva
BusinessWire - Tue Aug 18, 7:05AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted La Jolla orphan drug designation for two novel compounds for fibrodysplasia ossificans progressiva (FOP).
LJPC: 16.92 (-0.08)
La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors
BusinessWire - Tue Aug 18, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and Vanderbilt University (Vanderbilt) today announced an exclusive, worldwide research and license agreement covering Vanderbilt's research program and intellectual property rights relating to small-molecule kinase inhibitors designed to selectively block specific members of the bone morphogenetic protein (BMP) type-I receptor family.
LJPC: 16.92 (-0.08)
